Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
Cancer
|
October 8, 1998
Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party
S P Stenning, M C Parkinson, C Fisher, et al.
British Journal of Cancer
|
June 2, 2005
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
D P Dearnaley, S D Fossa, S B Kaye, et al.
Neurotoxicology and Teratology
|
September 4, 2023
Neurodevelopmental outcomes in children and adults with Fetal Valproate Spectrum Disorder: A contribution from the ConcePTION project
M Bluett-Duncan, D Astill, R Charbak, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 1, 1997
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party
G M Duchesne, S P Stenning, N Aass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
A Horwich, D T Sleijfer, S D Fosså, et al.
British Journal of Cancer
|
July 29, 1999
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
S D Fosså, S P Stenning, A Gerl, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
Cancer
|
October 8, 1998
Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party
S P Stenning, M C Parkinson, C Fisher, et al.
British Journal of Cancer
|
June 2, 2005
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
D P Dearnaley, S D Fossa, S B Kaye, et al.
Neurotoxicology and Teratology
|
September 4, 2023
Neurodevelopmental outcomes in children and adults with Fetal Valproate Spectrum Disorder: A contribution from the ConcePTION project
M Bluett-Duncan, D Astill, R Charbak, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 1, 1997
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party
G M Duchesne, S P Stenning, N Aass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
A Horwich, D T Sleijfer, S D Fosså, et al.
British Journal of Cancer
|
July 29, 1999
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
S D Fosså, S P Stenning, A Gerl, et al.
Page
of 6